Marco Ciufolini, PhD
Director & Scientific Advisor
Dr. Marco Ciufolini, co-founder of Integrated Nanotherapeutics, holds the position of Professor and Canada Research Chair in synthetic organic chemistry in the Department of Chemistry at the University of British Columbia. He is a leading expert in organic chemistry with significant expertise in medicinal chemistry. He has various awards to his credit, including most recently, the 2013 Canadian Society for Chemistry R. U. Lemieux Prize. He is a co-founder of AB Science, SA. This company was created to commercialize one of the drugs he invented: the tyrosine kinase inhibitor, Masitinib®, which is in Phase III trials for various cancerous and degenerative conditions. He is also a co-founder of Chrysalon SA, and Global Pharmaceutical Consulting, Inc., and is a consultant in medicinal and process chemistry for several pharmaceutical laboratories in the US and in Europe. Dr. Ciufolini's research on new reactions for the assembly of nitrogen-containing compounds and on the total synthesis of nitrogenous natural products is described in over 130 peer-reviewed articles and 7 book chapters. He is also an inventor on 30 patents.